Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ONT-380
ONT-380
With new name, new CEO, Cascadian now rolls out a new pivotal plan for lead cancer drug
Endpoints
Wed, 12/7/16 - 10:16 am
Oncothyreon
Cascadian
tucatinib
ONT-380
treatment-resistant breast cancer
breast cancer
6 Key Cancer Winners From ASCO Presentations
24/7 Wall St
Mon, 06/1/15 - 10:06 am
ASCO
Immunogen
mirevtuximab soravtansine
ONT-380
Oncothyreon
cabozantinib
Exelixis
VB-111
Vascular Biogenics
Immunomedics
sacituzumab govitecan
pacritinib
CTI BioPharma
Oncothyreon Breast Cancer Drug Exits ASCO '15 With Good Buzz
TheStreet.com
Mon, 06/1/15 - 09:43 am
Oncothyreon
breast cancer
ASCO
ONT-380
HER2-positive metastatic breast cancer